D
David Shimabukuro
Researcher at University of California, San Francisco
Publications - 21
Citations - 1204
David Shimabukuro is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Intensive care unit & Sepsis. The author has an hindex of 11, co-authored 21 publications receiving 956 citations.
Papers
More filters
Journal ArticleDOI
Prediction of Sepsis in the Intensive Care Unit With Minimal Electronic Health Record Data: A Machine Learning Approach.
Thomas Desautels,Jacob Calvert,Jana Hoffman,Melissa Jay,Yaniv Kerem,Lisa Shieh,David Shimabukuro,Uli K. Chettipally,Feldman,Christopher Barton,David J. Wales,Ritankar Das +11 more
TL;DR: InSight, a machine learning classification system that uses multivariable combinations of easily obtained patient data, is an effective tool for predicting sepsis onset and performs well even with randomly missing data.
Journal ArticleDOI
Multicentre validation of a sepsis prediction algorithm using only vital sign data in the emergency department, general ward and ICU
Qingqing Mao,Melissa Jay,Jana Hoffman,Jacob Calvert,Christopher Barton,David Shimabukuro,Lisa Shieh,Uli K. Chettipally,Grant S. Fletcher,Yaniv Kerem,Yifan Zhou,Ritankar Das +11 more
TL;DR: InSight is robust to missing data, can be customised to novel hospital data using a small fraction of site data and retains strong discrimination across all institutions.
Journal ArticleDOI
Effect of a machine learning-based severe sepsis prediction algorithm on patient survival and hospital length of stay: a randomised clinical trial.
TL;DR: This is the first randomised controlled trial of a sepsis surveillance system to demonstrate statistically significant differences in length of stay and in-hospital mortality.
Journal ArticleDOI
Injury and repair in lung and airways.
TL;DR: The rodent bleomycin model of lung fibrosis allows the use of molecular tools to dissect the cellular and subcellular processes leading to fibrosis and the elements of this response may provide therapeutic targets for the prevention of this devastating complication of ALI/ARDS.
Journal ArticleDOI
Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model.
Karine Faure,Junichi Fujimoto,Junichi Fujimoto,David Shimabukuro,Temitayo Ajayi,Nobuaki Shime,Nobuaki Shime,Kiyoshi Moriyama,Edward G. Spack,Jeanine P. Wiener-Kronish,Teiji Sawa +10 more
TL;DR: Mab166 and its Fab fragments have potential as adjuvant therapy for acute lung injury due to P. aeruginosa pneumonia and these parameters improved in rats that had received intratracheal instillation of either rabbit polyclonal anti-PcrV IgG, murine monoclonal anti- Pcr V IgG or Mab166 Fab-fragments in comparison with the control group.